After surviving numerous legal challenges and attacks by Republicans in Congress, plus a botched rollout in 2013, the controversial Patient Protection and Affordable Care Act (PPACA) now faces what may be its most serious threat: The program has been a money loser for the nation’s biggest insurance companies. The four leading U.S.

Orlistat, a weight-loss drug taken by millions of patients during the last two decades, has been buoyed by problematic clinical studies that “systematically understated” the drug’s potential harms, according to a new analysis.

The FDA is reminding health care facilities of Custom Ultrasonics’ May 6 device recall, and is advising users to stop using the company’s System 83 Plus automated endoscope reprocessor (AER) to reprocess duodenoscopes. By now, facilities should have transitioned to alternative methods for the reprocessing of duodenoscopes, according to the agency.

Positive results have been reported from a pivotal phase 3 study of RBP-6000 (buprenorphine monthly depot, Indivior PLC), an investigational drug for the treatment of opioid use disorder as part of a complete treatment plan that includes counseling and psychosocial support.

A new “super vaccine” with the ability to eliminate all 90 known strains of the world’s deadliest bacterial disease is being developed by a team at the University of Adelaide in South Australia.

A study conducted by the University of Oregon has found that hospital readmission rates are higher in Oregon communities with limited access to pharmacy services, according to an article posted on the HealthLeaders Media website.

Although the recently FDA-approved cholesterol-lowering drugs known as PCSK9 inhibitors could substantially reduce heart attacks, strokes, and cardiovascular deaths, they would not be cost-effective for use in patients with heterozygous familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD), with annual drug prices that need

Vertex Pharmaceuticals has provided an update on the ongoing phase 3 development program for its investigational compound VX-661 in combination with ivacaftor, which includes four studies that are expected to enroll more than 1,000 subjects with cystic fibrosis (CF).

OncoGenex Pharmaceuticals has announced results from the final analysis of its phase 3 AFFINITY study of custirsen in men with metastatic castrate-resistant prostate cancer (CRPC) whose disease has progressed after treatment with docetaxel.

An international team of scientists led by researchers at St. Jude Children’s Research Hospital in Memphis, Tennessee, has found a way to use CRISPR (clustered regularly interspaced short palindromic repeats) gene editing to help fix sickle-cell disease and beta-thalassemia in blood cells isolated from patients.

At the request of Governor Alejandro García Padilla, U.S. Department of Health and Human Services (HHS) Secretary Sylvia M.

As the number of states allowing medical marijuana grows—the total has reached 25 plus the District of Columbia—some are working to address physicians’ knowledge gap with training programs, according to a report from Kaiser Health News (KHN).

Mixed results have been reported from a phase 2b trial of voclosporin (Aurinia Pharmaceuticals) in patients with active lupus nephritis (LN).

Positive results have been reported from a phase 3, single-arm, open-label study of sufentanil sublingual tablets, 30 mcg (ARX-04, AcelRx Pharmaceuticals) in patients who presented to the emergency room with moderate-to-severe acute pain associated with trauma or injury.

Researchers at the University of Nebraska Medical Center have found that secondary infection with the methicillin-resistant Staphylococcus aureus (MRSA) bacterium often kills influenza patients because the flu virus alters the antibacterial response of leukocytes, causing them to damage the patients’ lungs instead of destroying the bacterium.